In our cohort, the frequency of JAK2 and PD-L2 amplification in relapsed/refractory DLBCL were 20% and 13.3%, which were within the range of ORR in the prior studies [18, 19]. The gene discussed is PDCD1LG2; the disease is diffuse large B-cell lymphoma.